Ancient Diseases Preventive Remedies Impact Factor
Preventive healthcare, or prophylaxis, consists of measures taken for disease prevention.[1] Disease and disability are affected by
environmental factors, genetic predisposition, disease agents, and lifestyle choices and are dynamic processes which begin before individuals realize they are affected. Disease prevention relies on anticipatory actions that can be categorized as primal,[2][3] primary, secondary, and tertiary prevention. Each year, millions of people die of preventable deaths. A 2004 study showed that about half of all deaths in the United States in 2000 were due to preventable behaviors and exposures.[4] Leading causes included
cardiovascular disease, chronic respiratory disease, unintentional injuries, diabetes, and certain infectious diseases.[4] This same study estimates that 400,000 people die each year in the United States due to poor diet and a sedentary lifestyle.[4] According to estimates made by the World
Health Organization (WHO), about 55 million people died worldwide in 2011, two thirds of this group from non-communicable diseases, including cancer, diabetes, and chronic
cardiovascular and
lung diseases.[5] This is an increase from the year 2000, during which 60% of deaths were attributed to these diseases.[5] Preventive healthcare is especially important given the worldwide rise in prevalence of
chronic diseases and deaths from these diseases. There are many methods for prevention of disease. One of them is prevention of teenage smoking through
information giving.[6][7][8][9] It is recommended that adults and children aim to visit their doctor for regular check-ups, even if they feel healthy, to perform disease screening, identify risk factors for disease, discuss tips for a healthy and balanced lifestyle.
High Impact List of Articles
-
Antibody drug conjugates in lymphoma
Nitya Nathwani & Robert Chen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Antibody drug conjugates in lymphoma
Nitya Nathwani & Robert Chen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 11
Acknowledgements: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials
Amresh Raina, Raymond L Benza
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials
Amresh Raina, Raymond L Benza
Review: Clinical Trail Outcomes: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
Relevant Topics in Clinical